ANNEXON INC (ANNX)
US03589W1027 - Common Stock
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...
Turnstone Biologics Appoints William Waddill to its Board of Directors
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
ANNX Stock Earnings: Annexon Beats EPS for Q4 2023
ANNX stock results show that Annexon beat analyst estimates for earnings per share the fourth quarter of 2023.
ANNX Stock Earnings: Annexon Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Annexon (NASDAQ:ANNX) just reported results for the fourth quarter of 2023.Anne...
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in...
Commit To Buy Annexon At $5, Earn 79.8% Annualized Using Options
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of...
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
Virtual event on Friday, March 1, 2024 at 10:00 AM ET Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison,...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases
ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in...
Annexon director purchases company shares worth $1M (NASDAQ:ANNX)
Muneer A Satter, Director of Annexon (ANNX), bought 350,000 shares at $2.88 each for $1M. A total of 9 insider trades have occurred in the past year.
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of...
Annexon stock rallies 30% on drug updates, $125M offering pricing (NASDAQ:ANNX)
Annexon (ANNX) shares surged 33% on positive updates for its drugs ANX007 and ANX1502, as well as the pricing of a $125M public offering. Read more here.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!
Annexon stock jumps on pricing of $125M public offering of common stock (NASDAQ:ANNX)
Annexon (ANNX) prices public offering of common shares and pre-funded warrants, expecting $125M in proceeds.
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
BRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a new class of...
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians